Association of Versican with Dermal Matrices and its Potential Role in Hair Follicle Development and Cycling  by du Cros, Diana L. et al.
Association of V ersican with Dermal Matrices and its 
Potential Role in Hair Follicle Development 
and Cycling 
Diana L. du Cros, Richard G. LeBaron,* and John R. Couchman 
Department of Cell Biology, University of Alabama at Birmingham, Birmingham, Alabama; aod *Division of Life Science, University 
ofTexas San Antonio, San Antonio, Texas, U.S.A. 
Versican is a member of the group of aggregating 
proteoglycans involved in matrix assembly and struc-
ture and in cell adhesion. We examined changes in 
the distribution of versican in mammalian skin, with 
emphasis on hair follicle development and cycling. In 
adult human skin, immunostaining for versican ap-
peared predominantly in the dermis, with intense 
staining of the reticular dermis. Weak staining was 
observed at the dermoepidermal junction and the 
connective tissue sheath of hair follicles. Versican 
expression was also noted in the reticular dermis of 
rat skin, within dermal papillae, and possibly associ-
ated with follicle basement membranes. During 
mouse hair follicle development, versican was not 
expressed until the hair follicles were beginning to 
produce fibers. With follicle maturation, versican 
expression intensified in the dermal papillae, reach-
V ersican is a member of a fami ly oflarge, aggregating proteoglycans that primarily bear chondroitin sulf.1te glycosaminoglycan side chains [1]. Other members of the famil y include aggrecan [2] , neurocan [3] , and brevican [4] . T h ese chondroitin sulfate proteogly-
cans (CSPGs) exhibit strong hyalnronan-binding capacity and fom1 
a group termed matrix hyaladherins [5] . As well as participating in 
matrix assembly and structure, these hyaluronan-binding proteins 
modulate hyaluronan function and are involved in cell-cell and 
ceU-matrLx adhesion, includ ing cell migration. In addition to their 
localization to the extracellul ar matrix (ECM) of cartilage, they are 
distributed in a variety of tissues such as skin, tendon, brain, aorta, 
and lung (reviewed in [6-8]). The core proteins of these CSPGs 
range in size from 80 to 400 kDa and contain a hya luronan-binding 
domain at the amino (N)-terminus and a lecti n-like motif at the 
carbo}l.-y (C)-terminus. 
Versican, originally identified in human fibrob lasts [9], exhibits 
strong binding affinity to hyaluronan through its N-terminal do-
main [10]. It also contains a sequence of epidermal growth factor 
(EGF)-like repeats and a complement-regu latory protein-like do-
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ing a maximum at the height of the growth phase 
(anagen), after which it diminished as the end of this 
phase approached. Versican immunoreactivity in the 
papillae decreased further during catagen and was 
absent from these structures during telogen. How-
ever, intense staining for versican was then observed 
in the neck regions of telogen follicles. As the folli-
cles entered the next hair cycle, versican disappeared 
from the necks and was again seen in the dermal 
papillae when follicles began producing fibers. This 
type of expression continued throughout subsequent 
hair cycles and is unlike any other dermal papilla 
component. The results of this study are consistent 
with a distinct supportive role for versican in the 
follicle matrices during hair follicle morphogenesis 
and cycling. Key words: proteoglyca.n expressiot~!luuuaul 
mouse. J Invest Demratol 105:426-431, 1995 
mam in the C-terminal portion of its protei.n core; the putative 
glycosaminoglycan attachment site are located in the middle 
region of the protein [1, 11]. 
The exact function of versican remains e lusive, although the 
molecul e appears to h ave several roles. It may be involved in in-
tercellular signaling through its lectin- and EGF-like sequences [11] 
and m ay also take part in cell recognition 11ia its interaction with 
other ECM components and cell surface molecules [1] . It has been 
proposed that PG-M, a chicken proteoglycan re lated to vers ican, 
may affect cell adhesion 11ia its chondroitin sulfate glycosam inogly-
can chains and C-terminus [1 2]. Furthermore, PG-M, although 
existing in various tissues, appears to be developmentally regulated 
in ti ssues such as the limb bud and retina, indi cating a ro le in cell 
signaling and behavior during morphogenesis [13,14]. 
Thus, the possibili ty exists that versican itself can also play an 
important ro le during development. Although several studies have 
reported changes in the expression of various other proteoglycans 
in the skin, we investigated the role of versican in developing skin. 
In this study, we describe spatial and temporal changes in the 
distribution of versican specifica Uy duri.ng hair foUicle development 
and the hair cycle. 
MATEIUALS AND METHODS 
Construction of Fusion Proteins All molecula r biology reagents were 
purchased fi-om International Biotechnologies, Inc. (New Haven. CT). 
Boehringer Mannheim Biochemicals (Indianapolis, lN), or Stratagene (La 
Jolla, CA) unJcss stated otherwise. All other chemicals. unless stated 
otherwise, were obtained from Sigma Chemical Co. (St. Louis. MO) . 
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Full-length versican recombinant eDNA was isolated as described earlier 
[1 OJ and was used as substrate in the polymerase chain reaction to amplify 
specific regions ofversican. Primer sequences that contain BmuHJ restriction 
sites toward their 5' end were determined using the published sequence of 
human versican eDNA and the program OLIGO (National Bioscience, Inc., 
Plymouth, MN). These primers were used to amplify fragments that span 
versican eDNA from base pairs (bp) 417-1336, 1537-2353 , and 5524-
6400. Polymerase chain reaction products containing versican fragments of 
911, 810, and 870 bp were separated on 1% agarose gels. Slices containing 
the appropriate fragment were excised and heated to 50°C for 2 min in the 
presence of3 vol (w/v) of6 M Nal and mixed with 1 ml of purification resin 
(Promega Corp., Madison, WI). The eDNA was eluted according to the 
manufacturer's instructions. The amplified products were subcloned into a 
unique Bam HI restriction site in the pBiuescript-derived T -vector (15] and 
electroporated into electrocompetent DH5a host cells. These cells were 
incubated in 1 ml of Luria broth (LB) medium at 37°C for 45 min and plated 
on nitrocellulose membranes overlaid on LB/ ampicillin plates (1 00 J..Lg 
ampicillin/ml). Mter overnight incubation at 37°C , the membranes were 
transferred to LB/ ampicillin plates containing 5-bromo-4-chloro-3-indolyl-
J3- D-galactopyranoside (X-Gal; 0.8 mg/100 ml plate) and isopropyl-13-D-
thiogalactopyranoside (IPTG; 9.5 mg/100 ml plate) and incubated further at 
37°C for several hours. White colonies were picked, and the plasmids were 
isolated by LiC12 precipitation. The versican eDNA fragments were excised 
with Bam HI, and the products were separated on 1% agarose gels . The 
appropriately sized fragments were purified as described above, subcloned 
into a unique BamHI restriction site in pQE-12 (QIAGEN Inc., Chatsworth , 
CA), and electroporated into electrocompetent M 15pREP4 host cells 
(QIAGEN lnc.). Transformed cells were incubated in 1 ml of LB medium 
at 37°C for 45 min and plated on LB/ampicillin/kanamycin plates (25 
J..Lg/ml kanamycin) . After overnight incubation at 37°C, randomly selected 
colonies were grown in 1.5 ml of LB/ampicillin/kanamycin medium until 
0.5 OD600 . Aliquots of each culture were stored at 4°C, and IPTG was 
added to the remaining cultures to a final concentration of 2 mM. The 
IPTG-containing cultures were incubated at 37°C for 3 h, and 0.1 ml of the 
suspension was washed in phosphate-buffered saline solution (PBS), boiled, 
and run on sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). Cultures that produced a protein with a molecular weight close to 
the theoretic molecular weight of the versican eDNA protein product and 
that reacted with crude antiversican antiserum were considered positive. 
The corresponding uninduced cultures (previously stored at 4°C) were 
stored at - 70°C in 15% glycerol. From these stocks, cultu res were grown 
and fusion proteins were isolated on Ni-chelate affinity columns (QlAGEN 
Inc.) according to the manufacturer's recommendations. The pm;fied fusion 
proteins were coupled to cyanogen-bromide-activated Sepharose (Sigma 
Chemical Co.). 
Versican Antibody Purification Crude versican antiserum from rab-
bits was fra ctionated with 50% ammonium sulfate, dialyzed to PBS, 
preabsorbcd with fetal bovine serum-Sepharose and an Escherichin coli 
acetone extract, and applied sequentially to versican fusion protein affinity 
columns. The eluates were further concentrated on Protein A-Sepharose 
(Pham1acia Bioteclu10logy. Piscataway, NJ) . Eluate fractions containing 
antibody were dialyzed to PBS. Bovine serum albumin (BSA) and sodium 
azide were added to give a final concentration of 0.5'% and. 0.02'!/o, 
respectively, and the anti-versican antibodies were designated VCl, VC2 , 
and VC3. 
The antigen used for production of whole versican antibody (VC) was 
human recombinant vcrsican, expressed by Chinese hamster ovary cells and 
isolated 11in anion exchange and gel filtration chromatography. The rabbit 
serum was preabsorbed against living and fonnaldehyde- fixed nontrans-
fe cted. Chinese hamster ovary cells, E. coli acetone lysate, feta l bovine 
serum-Sepharose, and BSA. 
Tissue Processing an~ Immunostaining Frozen sections of rat and 
human tissue were prepared. and stained as described previously (16, 17] with 
antibodies against basement membrane CSPG (BM-CSPG) core protein (16] 
and versican. 
Other skin samples were obtained. from the mid-dorsal region of a 
B6C3-based strain of mice. For fetal tissue , adult mice were mated. and the 
females were sacrificed to obtain fetuses at gestational days 13 to 18. Skin 
w as also obtained from sacrificed mice between the ages of newborn and 
day 30. All skin samples were removed from fresh ly sacriftced animals. The 
tissues were then fixed in acid-alcohol fixative (18], washed with 100% 
e thanol, cleared with xylene, and embedded in paraffin (Tissue-Prep; Fisher 
Scientific, Pittsburgh, PA). Tissue sections were cut at 5 {J.m with a rotary 
microtome (American Optical Corporation, Buffalo, NY) and affixed to 
glass slides. 
The paraffin sections were subjected to fluorescence immunostaining as 
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described previously (16,17] using antibodies against versican. The primary 
antibody localization was detected with fluorescein-isothiocyanate-cot~u­
gated goat anti-rabbit IgG (Cappel, Durham, NC) as secondary antibody. 
Negative controls included omission of the primary antibody or the use of 
preimmune rabbit serum in place of the prin1ary antibody. Some tissue 
sections were treated with 5% testicular hyaluronidase, Streptomyces hyalu-
ronidase (50 U/ml) , or chondroitinase ABC (0.1 U / ml; Seikagaku America, 
Inc. , Rockville, MD) before blocking for nonspecific proteins. Tissue 
sections were viewed on a Nikon Optiphot microscope equipped with 
epifluoresence illumination optics and appropriate filters. Photomicrographs 
were taken on Ilford HP-5 film . 
For peroxidase immunostaining, after clearing and rehydration, sections 
were treated with 10% peroxide for 5 min to inactivate endogenous 
peroxidases before blocking with 1% BSA. After the blocking step, the 
sections were rinsed in PBS then incubated for 40 min at 37°C with a 
biotinylated probe against hyaluronan (5 J..Lg/ ml PBS) [19]. The sections 
were rinsed in PBS; streptavidin-biotin-horseradish peroxidase complex 
(1 :400 dilution; Zymed Laboratories, Inc., San Francisco, CA) was then 
applied for 40 min at 37°C, followed by stable diaminobenzidine substrate 
solu tion (Research Genetics, !ric., Htmtsville, AL) to detect antibody 
binding. 
Western Blotting Protcoglycans isolated from the conditioned medium 
of primary human fibroblasts (passage 7) were applied to died1ylaminoethyl-
Sepharose (Pharmacia Biotechnology) , eluted with 1 M NaCI in 50 mM Tris 
buffer (pH 8), dialyzed to water, and lyophilized. The purified proteogly-
cans were treated with protease-free chondroitinase ABC or left untreated, 
loaded on a 4'Y,, to 20% precast polyacrylamide gel (Novex, San Diego, CA) 
(25 J..Lg of total protein per lane), and. subjected to SDS-PAGE. Afier electro-
phoresis, d1e material was elcctrotnmsferred onto Immobilon-P membrane 
(Millipore, Bedford, MA). The membrane was blocked with PBS containing 
1% BSA and 0.05% Tween 20 and d1en incubated with anti-versican antibody 
or with nonnal rabbit IgG, followed by incubation with goat anti-rabbit IgG 
conjugated to horseradish peroxidase. lnununoreactivity was detected wid1 
diaminobenzidine substrate. Molecular weights were estimated using 
prestained SDS-PAGE standards (BIO-RAD Laboratories, Richmond, CA). 
RESULTS 
Specificity ofVersican Antibodies All four antibodies against 
versican used in tlus study recogJlized the core protein of hwnan 
recombinant versican when expressed in primary human fibro-
blasts. Western blotting revealed a double polypeptide with an 
approximate molecular weight of 340 and 390 kDa after chon-
droitinase ABC treatment (Fig 1). These estimates agree with 
previous reports on t he size of the ve rsican protein core from 
IMR-90 lung fibroblasts [11) and from MG-63 cells [10). This 
characteristic double banding pattern may be generated by alterna-
tively spliced forms of versican [12,20). Alth ough all four antibod-
ies were used in indirect immunofluorescence microscopy, it was 
noted that VC2 was unable to detect versican it1 11i11o, and is not 
described further. Presumably the epitopes in this domain were 
either conformationally unsuitable or were obscured by interaction 
with other tissue components. 
Versican Is Distributed in Rat Skin and Aorta Antibodies 
VC1 and VC3 were used in indirect immunofluorescence micros-
copy on frozen rat tissue sections of newborn skin, aorta, and 
kidney. ln skin sections, staining of the reticular dennis was note d 
along with decreased staining in the papillary dennis (Fig 2A). 
Versican was also noted around hair follicles and within their 
dermal papillae (Fig 2, i11set), and was associated with the epithe-
lial-papilla interface , possibly the basement membrane (BM). The 
distribution of versican in interfollicular skin was quite unlike that 
reported for BM-CSPG, which was restricted to basement mem-
branes [17) (Fig 2B). However, a similar distribution of versican 
and BM-CSPG was noted in the dern1al papillae of anagen hair 
follicles. A detailed description of versican distribution in follicu lar 
development and cycling is given below. 
As positive controls, sections of rat aorta and kidney were stained 
for versican. The proteoglycan was abundantly present in the media 
and, to a lesser extent, in the adventitia of the aorta (Fig 2C), but 
was restricted to the ECM of major blood vessels of the kidney. No 
staining was associated with g lomeruli (results not shown). 
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Figure 1. Specificity of versican antibodies shown by Western 
blotting. Protcoglycans from the conditioned medium of primary human 
fibrob lasts were treated with protease-free chondroitinase ABC or left 
untreated. T he proteoglycans were separated on a 4% to 20% gradient 
polyacrylamide gel (25 J.Lg of total protein per lane) and subjected to SDS-
PAGE before transfer to lmmobilon-P membrane. The membrane was probed 
with anti-versican antibody or with nonnal rabbit IgG. Lnues 1 and J, untreated 
protcoglycans; laues 2 and 4, chondroitinase-AnC-treated proteoglycan. Anti-
versican antibodies recognize a diJfusely staining high-molecular-weight band 
in the untreated proteoglycans (laue 1) and lugh-molecu.lar-weight discrete 
versican protein core bands of apprm.cimatcly 340 and 390 kDa in the 
chondroitinase-treatcd sample (la ue 2) . Protcoglycans treated with nom1al 
rabbit lgG show nonspecific staitung at 175 kDa (laues 3 and 4). Similar 
background staining is seen in laues 1 and 2. Molecular weight markers (kDa) 
arc indicated (l~ji). Am1111, bottom of the gel loading wells. 
Versican Is Present in the Skin and Blood Vessels of Adult 
Human Skin Both VCl and VC3 antibodies stained human skin 
sections and revealed large amounts of dermal versican, with more 
intense sta ining again in the reticular de rmis (Fig 3A). W eak 
staining was also detected in the de rmoepidermal junction of scalp 
skin and connective tissue sheath of hair follicles (Fig 3B). V ersican 
was present in the perice llular matrix of sweat glands and duc ts (Fig 
3 q , perhaps associated with their basem ent membran es. Strong 
sta ining was also observed in p erivascular connective tissue oflarge 
vessels and associated with elastic fibers (Fig 3D). 
Versican Is Expressed in the Dermal Papillae During Hair 
Follicle Development in the Mouse D evelopment of the 
pelage or coat hair follicl es begins in m o use skin at approximately 
14 d of gestation. No immunostaining for versican was observed in 
initiating or developing hair follicles until gestational age 18 d (Fig 
4A) . Equivalent control sections did not show any staining (Fig 
4B). At 18 d ges tation, just before birth , the skin displays a range of 
follicl es at various stages of development, from the condensation 
stage through the plug stage to nearly mature follicles just begin-
ning to produce bai"r fibers; these latter follicl es are those first 
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Figure 2. Versican is present in rat skin and aorta . Vcrsican inun u-
noreactivity was observed in the reticu lar dermis of rat skin, with decreased 
staining in the papillary dermis (A). Versican was noted around hair follicl es 
and within dermal papillae (iuset). IJ1 intcrfollicular skin . the disuibution of 
vcrsican was quite unlike that of BM-CSPG, which was restricted to to 
basement membranes (B). An abundance of vers ican was observed in the 
media and adventitia of rat aorta (C). Bllr, 50 J.Lm . a, adventitia; d, dermis; 
dp , dermal papilla; c, ep idermis; I, lumen; m, media. 
initiated in the skin . Only these advanced follicles displayed light 
staining in their dermal papillae. N o immunoreactivity was ob-
served in the dermal components of less developed follicles, and 
non e was observed in the epidermal components of the follicles or 
in the epide rmis or basem ent m embranes. Staining in the upper 
keratinized layers o f the epidermis was nonspecific. Very fa int, 
diJfuse staining was observed throughout the upper dermis and in 
the pe rivascular connective ti ssue . As the follicles matured, staining 
for versican in the derm al papillae becam e more in tense (Fig 
4C,D), reaching maximum intensity at the heigh t of the growth 
phase , or anagen fV (results not shown) , but it began to diminish as 
the follicles approached the end of this phase . The fa int diffuse 
upper staining of the de rmis persisted throughout this period . 
Equivalent tissue sections pretreated with testicular hyaluronidase 
displayed either very weak or no staining for versican, indicative of 
release or destruction of the protein epitopes on versican recognized 
by the antibody. Versican staining was unaffected by pretreatment of 
sections with Streptomyces hyaluronidase or chondroirinase ABC (re-
sults not shown) , showing that removal ofhyaluronan o r chondroitin/ 
dennatan sulfate chain.s was not responsible for the e ffects noted with 
testicular hyaluronidase for the Joss of versican protein. 
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Figure 3. Versican is distributed in the skin and blood vessels of 
adult human tissue. Large amounts of dermal staining fo r vcrsican were 
d etected in hwnan skin, ·with rnorc in tense sta in ing found in the reticular 
dem1is (A). Staining was observed in the connective tissue sheath of hair 
follicles (nn·ows; B). Versican was present in the pericellular matrix of sweat 
glands and ducts (q, with strong staining detected in peri vascular connec-
tive tissue oflarge vessels and associated with elastic fibers (D). Bnr, 50 fL111 . 
d, d ennis; e, epidermis; hf, hair follicle. 
Versican Is Expressed in Dermal Papillae and Follicle Necks 
During the Mouse Hair Cycle After the growth period, hair 
follicles enter a short transition stage, catagen , then telogen, which 
is the resting phase of the hair cycle. Staining for vers ican in the 
dermal papillae diminished as the follicles entered the fina l stages of 
anagen . It is interesting that not only did staining intensity for 
versican lessen , but it also began to retreat down the p apillae until 
only the bases of the papillae showed staining (Fig SA) . During 
catagen, the hair follicle undergoes structural changes whereby th e 
epithelial cells surrounding th e de rmal papilla retreat toward the 
surface of the skin until , in telogen, the dermal papilla remains as a 
clwnp of cells attached to the base of the retreating epithelial 
column. All staining for versican disappeared from the dermal cells 
at this stage (Fig SB). However, intense versican irnmunostai.J1ing 
was observed in the "neck" regions of hair follicles in telogen (Fig 
SB). 
Versican stai.Jlli1g disappeared from the neck regions of the follicles 
as the follicles refonned and entered th e early stages of anagen of the 
second hair cycle (Fig SC). The follicles did not display any versican 
immw10reactivity w1ril d1ey were aga.i.J1 m ature and begimting to 
produce .fibers approxi.Jnately in anagen II , when the dermal papillae 
were agai.J1 positive (compare Fig SC, SD) . Staining for versican 
intensified in the papillae dnring the most vigo rous growth stage (Fig 
SE), but, as i.J1 the developing follicles, it decreased as the follicles 
approached the end of their J:,>rowth phase and disappeared as the 
follicles entered the catagen and telogen phases of the hail· cycle. 
DISCUSSION 
This report shows versican to be a widespread ECM component of 
rodent and human skin, with a uniqne pattern of distribution in 
murine hair follicle morphogenesis and cycling. It is m ost abundant 
in dermal matrix, particularly in human reticular dermis, and in the 
matrix of follicular dermal papillae. In human but not rodent skin, 
we a lso detected weak staining of the dermoepiderm aljunction and 
strong staining associated with elastic fibers, consistent w ith a 
previous report [20]. Versica.n is synthesized by cul tured hum an 
kerat:inocytes, which i.J1dicates that they may then be a source of 
versican in tlus b asement m embrane. We did not, however, 
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Figure 4. Versican is expressed in the dermal papillae of develop-
ing mouse hair follicles. fnun unostaining for vcrs ican \Vas not observed 
in the skin un til gestational day 18 , when light staining appeared in the 
dermal papillae (nmlll') of fo llicles producing hair fibe rs (A) . Contro] 
sections showed no staining (B). In newborn skin, vcrsican inllnunorcac-
tivity intensified in the dermal papillae of mature fo llicles (q, reaching 
ma"-imum intensity at the height of the growth phase about 9 d after birth 
(D). Bars. 50 fLm . d, dem1is; dp , dermal papill a; e, epidermis; f, fiber. 
observe staunug of the basa l keratinocytes as reported previously 
[20). T lus may be du e to diiferences in the antibodies used i.J1 the 
two studies, as diH:e rent regions of the versican molecule were used 
in each case . T h e polyclonal antibody used he re was prepared 
against w hole versican (Vo form) core protein, and re<Jctivity was 
noted with at least three distinct regions. T hese included a rebrion 
approximate to the hyaluronan-binding domain, indicating that a ll 
fonns of versican (PG-M) are recognized , regardless of the alternate 
splicing recentl y reported [21 J. Overa ll. we noted considerably less 
intense stainmg of rodent dermis than of human dermis, with the 
exception of hair follicl es m1d pet-ivascular tissue. Decreased sensi-
tivity of the antibodies, raised against human recombinant versican, 
to roden t tissue is not a likely explanation of o ur results, g iven th e 
intense staining of selected tissues. 
Hair fo llicle m o rphogen esis and subsequen t development are 
comp lex series of even ts that involve extensive celJ and matrix 
remodeli ng, and molecul es such as proteoglycans and growth 
factors have been i.Jnplica ted in these processes [17,22) . G iven the 
changes in th e distribution of other matrix molecules, including 
hyalnronan, in these processes, we have carefully examined versi-
can expression in muTine ski n development. 
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Figure 5. Versican is expressed in dermal papillae and follicle 
necks during the ~ouse hair cycle. As the hair follicles entered catagen 
(day 16), versican immunostaining retreated down the dermal papillae 
(mTow) until only the bases were stained (A) . Versican disappeared from the 
dermal components of the folucles during tclogen (day 19), only to appear 
intensely in the neck or bulge regions (mwws; B) . As the follicles began to 
reform in the early stages of the next hair cycle (day 24), versican staining 
disappeared from the neck regions (C) , remained absent from the dermal 
component of the folucle (mrow), and reappeared in the dermal papillae only 
when the folucles began again to produce hair fibers (D). Staining for 
versic:Ul intensified in the papillae during the most vigorous growth stage 
(E), but again decreased as the folucles neared the end of this hair cycle. 
Bars, 50 J..Lin. 
Hair follicle morphogenesis in the mouse begins relative ly late in 
development. The hair coat, or pelage, follicles of the mouse begin 
to grow at approximately 14 d of gestation and continue initiating 
up to a few days after birth (23,24]. Versican was not expressed 
during the early stages of follicle development, first appearing in the 
dermal papillae as the follicles were maturing and beginning to 
produce fibers. It has been shown previously that the dermal papilla 
is essential for fiber production to occur [25]. Staining for versican 
in the dermal papillae became more intense, reaching maximum 
intensity at the height of fiber production, but began to diminish as 
the follicles approached the end of anagen. 
Changes in expression of other proteoglycans have been noted 
previously during skin and follicle development and during the hair 
cycle (17,26,27]. BM-CSPG has a distribution through hair devel-
opment and cycling quite different from that seen here for versican 
[17] . Both CSPG and dermatan sulfate proteoglycan (DSPG) 
species exhibited age-related changes in developing rat skin [26]. In 
fetal skin, the amount of DSPG was found to be much higher 
(about 14 tin1es) than that of CSPG but, in the few days before 
birth, it declined at about half the rate of CSPG. The study 
suggested significant changes in proteoglycan synthesis and/or 
degradation , with greater changes shown in CSPG turnover than in 
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DSPG. Furthermore, a greater decrease in the relative proportions 
of sulfated glycosami.noglycan chains (chondroitin 4-sulfate versus 
chondroitin 6-sulfate) was noted in CSPGs compared with DSPGs 
in fetal and newborn skin. Although tlus study did not identify 
specific core proteins, these results suggest that proteoglycan 
expression varies dramatically during the transition from fetal to 
adult tissue. 
After anagen of the development stage, the follicles undergo 
cycling activity that continues throughout the life of the animal. At 
maturation, the pelage follicles undergo cycles of activity and rest, 
each cycle having three phases: anagen, catagen, and telogen 
[23,28,29]. As during follicle development, fiber production occurs 
during the anagen phase. At this most active growth stage, the 
follicles rapidly produce fiber and the skin is at its maxinmm 
thickness. 
Versican expression diminished at the end of anagen as the 
follicles began to enter catagen. It is interesting that versican inmm-
nostaining decreased by retreating down the papillae rmtil in telogen, 
the resting phase, all staining for versican disappeared from the dermal 
cells. This pattern has not been recorded for any other papilla 
component. Versican may then act as a specific marker of matri.x 
changes in the wuque papilla ECM. As staining disappeared during 
catagen and telogen, intense versican inunrmostaining was then ob-
served in the neck regions of hair follicles in telogen. This region of the 
follicle is apical to the insertion point of the arrector pili muscle but 
distal to the sebaceous gland ducts, and is in the bulge area wherein 
resides a putative stem cell population reputedly responsible for 
control of the hair cycle [30,31]. CSPG in tlus area has been observed 
previously using a carbohydrate-specific antibody [32]. Because this 
antibody recognizes chondroitin sulfate, it is possible that it detected 
versican. The function of versican in this area and at tlus particular 
phase of the hair cycle is unknown, but it may be involved in providing 
a suitable matrix for maintenance of the stem cells before their 
activation at the beginning of the hair cycle. 
Versican staining disappeared from the neck regions of tl1e 
follicles as they entered the early stages of anagen of the next hair 
cycle. No versican inmmnoreactivity was detectable until the 
follicles were beginning to produce fibers in about nud-anagen, 
when the dem1al papillae were again positive. Again, tlus is unlike 
any other dermal papilla matrix component. Staining for versican 
intensified in the papillae during the most vigorous growth stage, 
but, as in the developing follicles, it decreased as the follicles 
approached the end of their growth phase and disappeared as the 
follicles entered the catagen and telogen phases of tl1e next hair 
cycle. 
Expression of versican thus appears to correlate not with the 
proliferative activity of follicular epithelium, but rather with follicle 
differentiation. The epidermally derived cells surrounding tl1e 
dermal papilla u1 the follicle bulb have a number of fates, differen-
tiating to form the itmer root sheath and the hair fiber itself. 
Previous studies have shown that the dem1al papilla of rodents 
produces a unique ECM containing basement membrane compo-
nents such as BM-CSPG, perlecan, type IV collagen, and laminin, 
but, unlike the ECM of the dennis, it lacks most interstitial collagen 
[33,34]. However, if papilla cells are grown under culture condi-
tions, their matrix reverts in time, becoming similar to the matri.x 
produced by dermal fibroblasts, and the cells lose their ability to 
u1duce hair growth [35]. Because dermal papilla cells do not 
constitute a population of rapidly dividing cells, even during the 
most active follicular growth stage of anagen, it is not likely that the 
intense stau1ing for versican in the papillae is related to cellular 
proliferation. More likely, the molecule is part of the papilla ECM, 
providing a unique support system for these cells during the 
inductive processes of hair follicle development and cycling. 
Further evidence for a supportive role is provided by the 
presence of versican in the bulge region of the follicles duru1g 
telogen, where it may help to maintain tl1e viability of the stem cell 
population. In addition, a comparison of previous data [36] and this 
report indicates that the expression of versican in developing and 
cycling hair follicles is closely correlated with tl1at of hyaluronan. 
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Hyaluronan is thought to m aintain th e extrace llu.lar space between 
cells; its loss permits cellular condensati on to occur [36,3 7]. Tlus is 
illustrated during hair follicle morphogenesis as h yaJuronan is 
conspicuously absent from the developing follicle until it reaches 
maturity; h yaluron an is then expressed in the matrix of the dennal 
papilla [3 6]. An inverse correlation between the expressio n of 
hyaluronan and on e of its receptors, CD44, has also been show n in 
the developing hai r follicle [36]. It is therefore possible that 
hyaluronan and vers ican interact in dermal papilla matrix, support-
ing the notion that hyaluronan is not preferentially involved in 
interactions w ith the CD44 class of receptors. Versican has been 
shown previously to bind hya luronan through its N-terminal 
glob ular region and to modulate hyaluronan function [5, 1 0]. It has 
been suggested that vers ican acts as a bridge between hyaluronan 
and cell surf.Kes, perhaps holding hyaluronan in place [10]. T lus 
role is supported by fmdings that the versican-rela ted proteoglycan 
PG-M is involved in the binding of hyaluron an to both fibronectin 
and type I collagen [38]. In the present study, versican sta ining was 
redu ced or eliminated b y testicular hya.luro nidase treatment, reveal-
ing a loss of protein epitopes o n the core protein. However, staining 
was not reduced by treatment with the hya luronan-specific en-
zyme, S lreplowyres hyaluronidase, or by ch ondroitinase ABC. Ver-
sican is substituted with chondroitin sulfitte chains, whose presence 
is, t herefore, not solely responsible for stable interactions in con-
nective tissue. Similarly, though versicru1 interacts with hyaluronan, 
deple tion of tlus glycosaminoglyca n does not lead to a detectable 
loss of versican from tissue sections. Versican may undergo other 
in1portant protein-protein interactions in the matrix, which are 
disrupted by the protcases present in commercia l testicu lar hyalu-
ronidase. 
Although specific matrix molecules, besides hyaluronan, to 
which versican binds ha ve not yet been identified in 11ivo, it can be 
envisioned that versican has a distinct supportive role during hair 
follicle morphogenesis and cycl ing by forming an integral part of 
the matrix scafFold. 
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